Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0FZ1Z
|
||||
| Former ID |
DIB014776
|
||||
| Drug Name |
Doxorubicin-CEA conjugate
|
||||
| Synonyms |
DOX-CEA; Doxorubicin-CEA conjugate, Immunomedics
|
||||
| Indication | Breast cancer [ICD9: 174, 175; ICD10:C50] | Terminated | [1] | ||
| Company |
Immunomedics Inc
|
||||
| Target and Pathway | |||||
| Target(s) | Human DNA | Target Info | Modulator | [2] | |
| DNA topoisomerase II | Target Info | Modulator | [2] | ||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007194) | ||||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.